메뉴 건너뛰기




Volumn 3, Issue 8, 2012, Pages 833-842

Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells

Author keywords

Cellular localization; Death receptors; Drug resistance; Targeted cancer therapy

Indexed keywords

DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR 1;

EID: 84868614960     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (44)

References (37)
  • 1
    • 45849115453 scopus 로고    scopus 로고
    • TRAIL death receptors as tumor suppressors and drug targets
    • Finnberg N, El Deiry WS. TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle 2008;7:1525-8.
    • (2008) Cell Cycle , vol.7 , pp. 1525-1528
    • Finnberg, N.1    El Deiry, W.S.2
  • 2
    • 0037273848 scopus 로고    scopus 로고
    • Apo2L/TRAIL and its death and decoy receptors
    • LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003;10:66-75.
    • (2003) Cell Death Differ , vol.10 , pp. 66-75
    • LeBlanc, H.N.1    Ashkenazi, A.2
  • 4
    • 76749170208 scopus 로고    scopus 로고
    • Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulation
    • Verbrugge I, Maas C, Heijkoop M, Verheij M, Borst J. Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulation. Cell Death Differ 2010;17:551-61.
    • (2010) Cell Death Differ , vol.17 , pp. 551-561
    • Verbrugge, I.1    Maas, C.2    Heijkoop, M.3    Verheij, M.4    Borst, J.5
  • 5
    • 40449134499 scopus 로고    scopus 로고
    • Tumor necrosis factor: renaissance as a cancer therapeutic
    • Daniel D, Wilson NS. Tumor necrosis factor: renaissance as a cancer therapeutic? Curr Cancer Drug Targets 2008;8:124-31.
    • (2008) Curr Cancer Drug Targets , vol.8 , pp. 124-131
    • Daniel, D.1    Wilson, N.S.2
  • 6
    • 84858423116 scopus 로고    scopus 로고
    • Systemic use of tumor necrosis factor alpha as an anticancer agent
    • Roberts NJ, Zhou S, Diaz LA, Jr., Holdhoff M. Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget 2011;2:739-51.
    • (2011) Oncotarget , vol.2 , pp. 739-751
    • Roberts, N.J.1    Zhou, S.2    Diaz Jr., L.A.3    Holdhoff, M.4
  • 7
    • 0033764170 scopus 로고    scopus 로고
    • Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)
    • Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat Biotechnol 2000;18:1185- 90.
    • (2000) Nat Biotechnol , vol.18 , pp. 1185-1190
    • Curnis, F.1    Sacchi, A.2    Borgna, L.3    Magni, F.4    Gasparri, A.5    Corti, A.6
  • 8
    • 67649998165 scopus 로고    scopus 로고
    • Biodistribution of TNF-alpha-coated gold nanoparticles in an in vivo model system
    • (Lond)
    • Goel R, Shah N, Visaria R, Paciotti GF, Bischof JC. Biodistribution of TNF-alpha-coated gold nanoparticles in an in vivo model system. Nanomedicine (Lond) 2009;4:401-10.
    • (2009) Nanomedicine , vol.4 , pp. 401-410
    • Goel, R.1    Shah, N.2    Visaria, R.3    Paciotti, G.F.4    Bischof, J.C.5
  • 11
    • 49049086338 scopus 로고    scopus 로고
    • Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL)
    • Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008;26:3621-30.
    • (2008) J Clin Oncol , vol.26 , pp. 3621-3630
    • Ashkenazi, A.1    Holland, P.2    Eckhardt, S.G.3
  • 12
    • 52649109068 scopus 로고    scopus 로고
    • The TRAIL apoptotic pathway in cancer onset, progression and therapy
    • Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8:782-98.
    • (2008) Nat Rev Cancer , vol.8 , pp. 782-798
    • Johnstone, R.W.1    Frew, A.J.2    Smyth, M.J.3
  • 14
    • 72449164087 scopus 로고    scopus 로고
    • Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells
    • Yoshida T, Zhang Y, Rivera Rosado LA, Zhang B. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells. Mol Cancer Res 2009;7:1835- 44.
    • (2009) Mol Cancer Res , vol.7 , pp. 1835-1844
    • Yoshida, T.1    Zhang, Y.2    Rivera Rosado, L.A.3    Zhang, B.4
  • 15
    • 57749097095 scopus 로고    scopus 로고
    • TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5
    • Zhang Y, Zhang B. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 2008;6:1861-71.
    • (2008) Mol Cancer Res , vol.6 , pp. 1861-1871
    • Zhang, Y.1    Zhang, B.2
  • 16
    • 47749089820 scopus 로고    scopus 로고
    • Regulation of TNFR1 and CD95 signalling by receptor compartmentalization
    • Schutze S, Tchikov V, Schneider-Brachert W. Regulation of TNFR1 and CD95 signalling by receptor compartmentalization. Nat Rev Mol Cell Biol 2008;9:655- 62.
    • (2008) Nat Rev Mol Cell Biol , vol.9 , pp. 655-662
    • Schutze, S.1    Tchikov, V.2    Schneider-Brachert, W.3
  • 18
    • 4444341939 scopus 로고    scopus 로고
    • Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles
    • Schneider-Brachert W, Tchikov V, Neumeyer J, Jakob M, Winoto-Morbach S, Held-Feindt J, et al. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 2004;21:415-28.
    • (2004) Immunity , vol.21 , pp. 415-428
    • Schneider-Brachert, W.1    Tchikov, V.2    Neumeyer, J.3    Jakob, M.4    Winoto-Morbach, S.5    Held-Feindt, J.6
  • 22
    • 68049125070 scopus 로고    scopus 로고
    • TRAIL induces endocytosis of its death receptors in MDA-MB-231 breast cancer cells
    • Zhang Y, Yoshida T, Zhang B. TRAIL induces endocytosis of its death receptors in MDA-MB-231 breast cancer cells. Cancer Biol Ther 2008;8.
    • (2008) Cancer Biol Ther , pp. 8
    • Zhang, Y.1    Yoshida, T.2    Zhang, B.3
  • 23
    • 76749110412 scopus 로고    scopus 로고
    • A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies
    • Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, et al. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 2010;16:1256-63.
    • (2010) Clin Cancer Res , vol.16 , pp. 1256-1263
    • Camidge, D.R.1    Herbst, R.S.2    Gordon, M.S.3    Eckhardt, S.G.4    Kurzrock, R.5    Durbin, B.6
  • 24
    • 77956414973 scopus 로고    scopus 로고
    • Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer
    • Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010;28:2839-46.
    • (2010) J Clin Oncol , vol.28 , pp. 2839-2846
    • Herbst, R.S.1    Eckhardt, S.G.2    Kurzrock, R.3    Ebbinghaus, S.4    O'Dwyer, P.J.5    Gordon, M.S.6
  • 25
    • 79955995604 scopus 로고    scopus 로고
    • Drozitumab, a human antibody to death receptor 5, has potent anti-tumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response
    • Kang Z, Chen J, Yu Y, Li B, Sun SY, Zhang B, et al. Drozitumab, a human antibody to death receptor 5, has potent anti-tumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin Cancer Res 2011.
    • (2011) Clin Cancer Res
    • Kang, Z.1    Chen, J.2    Yu, Y.3    Li, B.4    Sun, S.Y.5    Zhang, B.6
  • 26
    • 79952336885 scopus 로고    scopus 로고
    • Combined modality therapy with TRAIL or agonistic death receptor antibodies
    • Amm HM, Oliver PG, Lee CH, Li Y, Buchsbaum DJ. Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol Ther 2011;11:431-49.
    • (2011) Cancer Biol Ther , vol.11 , pp. 431-449
    • Amm, H.M.1    Oliver, P.G.2    Lee, C.H.3    Li, Y.4    Buchsbaum, D.J.5
  • 27
    • 84857862604 scopus 로고    scopus 로고
    • Three-dimensional microscopy characterization of death receptor 5 expression by over-activated human primary CD4 T cells and apoptosis
    • Barblu L, Herbeuval JP. Three-dimensional microscopy characterization of death receptor 5 expression by over-activated human primary CD4 T cells and apoptosis. PLoS One 2012;7:e32874.
    • (2012) PLoS One , vol.7
    • Barblu, L.1    Herbeuval, J.P.2
  • 29
    • 0000005230 scopus 로고    scopus 로고
    • Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells
    • Zhang XD, Franco AV, Nguyen T, Gray CP, Hersey P. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol 2000;164:3961-70.
    • (2000) J Immunol , vol.164 , pp. 3961-3970
    • Zhang, X.D.1    Franco, A.V.2    Nguyen, T.3    Gray, C.P.4    Hersey, P.5
  • 31
    • 67249100235 scopus 로고    scopus 로고
    • Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy
    • Leithner K, Stacher E, Wurm R, Ploner F, Quehenberger F, Wohlkoenig C, et al. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy. Lung Cancer 2009;65:98-104.
    • (2009) Lung Cancer , vol.65 , pp. 98-104
    • Leithner, K.1    Stacher, E.2    Wurm, R.3    Ploner, F.4    Quehenberger, F.5    Wohlkoenig, C.6
  • 32
    • 83355163382 scopus 로고    scopus 로고
    • Importin beta1 protein-mediated nuclear localization of death receptor 5 (DR5) limits DR5/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells
    • Kojima Y, Nakayama M, Nishina T, Nakano H, Koyanagi M, Takeda K, et al. Importin beta1 protein-mediated nuclear localization of death receptor 5 (DR5) limits DR5/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells. J Biol Chem 2011;286:43383-93.
    • (2011) J Biol Chem , vol.286 , pp. 43383-43393
    • Kojima, Y.1    Nakayama, M.2    Nishina, T.3    Nakano, H.4    Koyanagi, M.5    Takeda, K.6
  • 33
    • 67349162130 scopus 로고    scopus 로고
    • Tumour necrosis factor and cancer
    • Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009;9:361-71.
    • (2009) Nat Rev Cancer , vol.9 , pp. 361-371
    • Balkwill, F.1
  • 34
    • 2442678063 scopus 로고    scopus 로고
    • Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor
    • Demidenko ZN, Blagosklonny MV. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res 2004;64:3653-60.
    • (2004) Cancer Res , vol.64 , pp. 3653-3660
    • Demidenko, Z.N.1    Blagosklonny, M.V.2
  • 35
    • 80053410931 scopus 로고    scopus 로고
    • Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link
    • Fulda S. Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link. Oncotarget 2011;2:418-21.
    • (2011) Oncotarget , vol.2 , pp. 418-421
    • Fulda, S.1
  • 36
    • 3042800912 scopus 로고    scopus 로고
    • Rac1 inhibits apoptosis in human lymphoma cells by stimulating Bad phosphorylation on Ser-75
    • Zhang B, Zhang Y, Shacter E. Rac1 inhibits apoptosis in human lymphoma cells by stimulating Bad phosphorylation on Ser-75. Mol Cell Biol 2004;24:6205-14.
    • (2004) Mol Cell Biol , vol.24 , pp. 6205-6214
    • Zhang, B.1    Zhang, Y.2    Shacter, E.3
  • 37
    • 34548695886 scopus 로고    scopus 로고
    • TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma
    • Sanlioglu AD, Korcum AF, Pestereli E, Erdogan G, Karaveli S, Savas B, et al. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Int J Radiat Oncol Biol Phys 2007;69:716-23.
    • (2007) Int J Radiat Oncol Biol Phys , vol.69 , pp. 716-723
    • Sanlioglu, A.D.1    Korcum, A.F.2    Pestereli, E.3    Erdogan, G.4    Karaveli, S.5    Savas, B.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.